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Abstract: Invasive Aspergillosis (IA) is one of the most common invasive fungal diseases and is
accompanied by high morbidity and mortality. In order to maximize patient outcomes and survival,
early and rapid diagnosis has been shown to be pivotal. Hence, diagnostic tools aiding and improving
the diagnostic process are ambitiously searched for. In this context, polymerase chain reaction
(PCR) may represent a potential candidate. Its additional value and benefits in diagnosis have been
demonstrated and are scientifically established. Nevertheless, standardized and widespread usage
is sparse because several factors influence diagnostic quality and need to be considered in order to
optimize diagnostic performance and outcome. In the following review, the current role of PCR
in the diagnosis of IA is explored, with special focus on the strengths and limitations of PCR in
different settings.
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1. Blood Aspergillus PCR
1.1. Introduction
Polymerase chain reaction (PCR)-based diagnostic methods revolutionized medicine. However,
the exact role of PCR in diagnosing invasive fungal infections (IFIs) is still under debate, given
the lack of standardization and large variation of diagnostic performance across studies and settings.
Several PCR-based methods are currently used in routine clinical practice to diagnose or rule out
suspected IFI. Performance of blood PCR methods are highly dependent on patient cohort characteristics
including accompanying pretest probability and antifungal prophylaxis, and also PCR characteristics,
such as number of cycles and limit of detection. A reliable diagnostic assay is specifically needed
for IA, as IA remains associated with high morbidity and mortality [1,2]. IA remains difficult
to diagnose using culture-based methods given the low sensitivity of Aspergillus recovery from
blood and bronchoalveolar lavage fluid (BALF) [3]. Consequently, antigen testing—in particular
galactomannan (GM) testing—has emerged as the gold-standard for diagnosing IA. As performance of
GM testing is still less than perfect and turnaround time varies [4,5], the search for improved biomarker
tests continues, with the focus on point-of-care lateral flow device tests [6–8], immunologic markers,
markers of iron acquisition [9,10], and PCR testing [1]. Even though IA remains the predominant mold
infection in immunocompromised hosts, its prevalence remains low at 0.2% of hospital admissions
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among patients considered to be at risk for IFIs [11]. The low prevalence of IA, together with often
non-specific clinical or radiologic signs of IA [12], pose significant challenges to diagnostic strategies.
While blood PCR has been used as an aid in the diagnosis of IA for almost three decades,
broad implementation has been limited given the lack of standardization of PCR assays [13] and variable
performances in different settings [14,15]. Recent guidelines for the diagnosis and management
of Aspergillus disease moderately recommended PCR on blood samples for the diagnosis of IA,
with a quality of evidence (QoE) Level II [16], and very recently PCR has also been included
as mycological criterion in consensus definitions of IA [17]. Despite these advances, blood PCR is still
not used widely in clinical routine. In this critical review of available literature we will try to clarify
the role of blood PCR for diagnosing IA, focusing on its strengths (“the good”), limitations (“the bad”),
and outlining clinical settings and patient cohorts where performance of blood PCR has been largely
disappointing (“the ugly”).
1.2. The Good
One of the major strengths of blood Aspergillus PCR is its high sensitivity and negative predictive
value (NPV) in severely immunocompromised patients with underlying hematological malignancies
in settings where antifungal prophylaxis is not used. A 2019 published systematic review highlighted
a mean sensitivity and specificity of 79.2% and 79.6% for a single positive test result and 59.6%
and 95.1% for two consecutive positive results when performing PCR on blood samples (serum or
whole blood). The majority of investigated cohorts were hematological malignancy patients at highest
risk for IA (i.e., neutropenic cancer patients, hematopoietic stem cell transplant (HSCT) recipients) [18].
In this setting with high prevalence of 16.3%, the NPV was 95.1% for one negative test result and 92.4%
for two negative test results [18]. Higher NPVs are therefore expected in a lower prevalence setting,
indicating that a single PCR-negative test result may be adequate to exclude a diagnosis of IA.
Another benefit of blood PCR is its higher potential to diagnose IA earlier compared to GM.
Several studies have shown that Aspergillus DNA in the bloodstream precedes the release of GM
into the bloodstream and thus PCR positivity is indicative of Aspergillus exposure prior to other
biomarkers becoming detectable or clinical signs or symptoms of the disease being noticeable [19,20].
As a consequence, positive test results, particularly when PCR is combined with other molecular
diagnostic tests such as GM (increase of specificity), may be used to initiate further diagnostic
work-up. The latter includes bronchoscopy with biopsy or BALF, and eventually initiation of
antifungal therapy [21,22]. Although Aspergillus DNA correlates quantitatively to serum GM levels [23],
it is important to remember that at different stages of invasive disease different antigens may be
detectable in patient blood [24]. This highlights the importance of combining different biomarkers in
the diagnostic process and to repeat available diagnostic tests if they turn out negative, but clinical
suspicion of IA is still high. In high-risk settings that don’t use mold-active antifungal prophylaxis,
screening strategies with serum GM and blood PCR could therefore represent an alternative to empiric
antifungal treatment strategies (i.e., based on neutropenic fever not responsive to antibacterial therapy),
reducing the use and cost of antifungal agents. Additionally, potentially unnecessary drug exposure
and toxicity, associated with severe side effects, could be avoided [25,26]. In contrast, screening
for IA is not recommended in settings that use mold-active prophylaxis, which has been shown to
be highly effective in those at the highest risk for developing IA, decreasing IA prevalence to 3%
and below [27–29]. This may be due to the low prevalence of IA in those settings, which reduces
the positive predictive value (PPV) of a positive PCR test result, as well as the fact that antifungals may
inhibit PCR and therefore limit diagnostic utility, as discussed in more detail later in this review [30,31].
The same limitations also apply for serum GM testing [32]. Thus, general screening for IA in patients
on mold-active prophylaxis is currently not recommended, where both PCR and GM should instead
be used for targeted testing in the case of clinical or radiological suspicion of breakthrough IA [5,27].
Aspergillus fumigatus (A. fumigatus) is the most common cause for IA [33,34] and most prior studies
have focused on the evaluation of PCR assays for this species. Epidemiology of IA globally varies
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and species other than A. fumigatus are increasing in prevalence [35]. Additionally, non-Aspergillus
molds occur more frequently due to the increasing use of antifungal prophylaxis and more intensive
immunosuppressive therapies [36]. As a result, it is important that Aspergillus PCR assays show
a high analytical specificity and are capable of differentiating between several Aspergillus species
without cross-reacting to other molds, because non-Aspergillus molds may require different anti-fungal
treatment and some Aspergillus species can be intrinsically resistant to polyenes or azoles [37]. To date,
Aspergillus PCR is the only non-culture-based assay that is able to differentiate Aspergillus spp. down
to the species level. However, due to inferior detection of Aspergillus species other than A. fumigatus,
current recommendations prefer the use of genus-specific PCR assays rather than species-specific
ones [38].
A significant strength of some blood Aspergillus PCR assays is their ability to detect major
single nucleotide polymorphisms, implying environmentally acquired resistance [39]. Increasing
Aspergillus resistance to antifungal drugs is an emerging problem in clinical practice in some parts of
the world [40–42]. As stated above, resistance can be intrinsic, but the problem of increasing resistance
is mostly driven by environmentally acquired resistance due to exposure to azole compounds, either in
clinical settings or—more often—in agriculture where azoles are used commonly as fungicides [43].
Acquired azole resistance is primarily found in A. fumigatus. Most azole resistance patterns are caused
by point mutations in the cyp51A gene. Two commercially available PCR kits are able to detect
the most relevant point mutations in this gene and therefore azole resistance, namely the AsperGenius®
and MycoGENIE®, with similar diagnostic performance [44]. However, current data is insufficient
and further evaluation of assays targeting resistance genes is required.
Whether serum or whole blood samples should be used to perform PCR remains a matter of
debate. While sensitivities reported in studies using serum samples were comparable to those using
whole blood samples [45–47], there are studies indicating a trend towards higher sensitivity of whole
blood/plasma samples compared to serum samples [45,48]. A possible explanation for the higher
sensitivity in plasma/whole blood samples is the higher amount of cell-free DNA in plasma samples
compared to serum samples. This may be the consequence of clotting in serum samples as DNA
concentrations in clots were found to be higher than those in serum, leading to further decrease
and a lower abundance of circulating Aspergillus DNA in serum during invasive disease [49,50]. Still,
PCR testing from serum has the advantage that other biomarkers for IA like galactomannan can be
measured in the same sample and thus reducing the amount of blood drawn.
In summary, evidence supports that for the diagnosis of IA in neutropenic patients, Aspergillus PCR
in blood is as good as serum GM and superior to 1,3-beta-d-glucan, which cross reacts with Candida spp.
and may be elevated in various conditions associated with fungal translocation from the gut [51].
Another benefit of PCR is the potential detection of acquired azole resistance. Consequently, PCR
was recently included in the new European Organization for the Research and Treatment of Cancer
(EORTC)/Mycoses Study Group (MSG) consensus definitions of IA [17].
1.3. The Bad
While Aspergillus PCR is now well established for use in neutropenic patients with underlying
hematological malignancies in settings that do not use mold-active prophylaxis, its usefulness in
other settings remains unclear. Importantly, the pathogenesis of IA differs between neutropenic
and non-neutropenic patients [52,53], impacting clinical presentation, radiological findings,
and diagnostic test results in the mycology laboratory [54]. Neutropenic patients usually develop
angio-invasive disease associated with increased serum GM levels, but sensitivities of serum GM
decrease to 30% and less in non-neutropenic patients who primarily develop tissue invasive disease with
only limited angio-invasion [52,53,55–57]. In contrast, BALF GM testing remains reliable independent
of neutrophil count, as the lungs are usually the primary site of infections caused byAspergillus [1,58–60].
Similarly, PCR testing of blood specimens seems to have limited diagnostic ability in non-neutropenic
patients, with sensitivities as low as 11% in intensive care unit (ICU) patients [61], while sensitivity
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and overall diagnostic performance of BALF PCR testing has been shown to be significantly better,
reaching sensitivities of 44%–100% [61–64]. Even in patients with hematological malignancies but
without neutropenia, Aspergillus PCR from blood samples proved to be insufficiently sensitive to be
diagnostically useful after day 100 post stem cell transplantation [65]. As patients after allogeneic
stem cell transplantation may develop graft-versus-host disease and therefore require long-term
immunosuppressive treatment putting these patients on risk for IA for a long period of time, the utility
of blood PCR for diagnosis of IA after engraftment is questionable. The limited utility of PCR from
blood specimens in non-neutropenic patients is a very relevant limitation given that the prevalence of IA
continues to increase in non-neutropenic patients with other severe underlying diseases. This includes
patients in the ICU where prevalence rates vary between 0.33%–19% [66–69], solid organ transplant
recipients [70], patients receiving systemic glucocorticoids [71], patients with underlying respiratory
conditions [66,72], patients with solid cancers [66,73], and other patient groups [66,74].
Positive Aspergillus PCR in BALF samples should also be interpreted with caution and cannot be
used as a sole marker for the presence of IA. This is due to the fact that different cohorts of patients with
structural or functional lung disease are likely to be colonized with Aspergillus in the lower respiratory
tract but to not necessarily develop invasive disease as long as no additional immunosuppressive
disease or treatment is present [75–79]. In such cases, a positive BALF PCR result may represent
either colonization of the patient or actual invasive disease. To discriminate these two entities in
a patient with a positive lower respiratory tract, Aspergillus PCR, clinical presentation, imaging studies,
and other biomarkers are helpful. Contamination of the obtained specimen during sampling or during
processing in the laboratory may also cause a false positive PCR result.
Importantly, standardization of blood PCR remains a tricky challenge and complicates comparison
and generalization of study results. While a variety of commercially available PCR assays are currently
in use, only a few have been investigated in large cohort studies (e.g., AsperGenius®, MycAssay
Aspergillus®, MycoGENIE®) [44]. The mentioned assays have shown comparable results in different
studies. For BALF samples in hematological patients, sensitivities and specificities were reported
reaching from 80% to 92.9% and 80% to 97.1% [80–82]. In particular, sensitivity has been shown to be
significantly lower in serum samples compared to respiratory samples [83].
The absence of general recommendation on which PCR tests are preferable and the existence of
a vast number of in-house assays, most of which are lacking external validation, is restraining the use
of PCR in many countries and impairing standardization. Not only the nature of samples studied
(whole blood, serum, plasma) and volume of sample tested, but also specimen processing and DNA
extraction methods, gene targets, amplification platforms, detection methodologies, and definitions of
PCR positivity differ widely between these PCR assays. While some assays rely on a high number
of amplification circles to lower the limit of detection to below one colony forming unit (CFU)/mL
and thereby increase sensitivity, this comes at the cost of specificity, potentially driven by low-level
fungal translocation which may occur in a variety of diseases [51,84–88]. Standardization in terms of
defining a positive PCR is therefore needed. Technical methodology such as time to reporting, access to
testing centers, and frequency of testing also needs to be optimized in order to acquire reliable results
within a reasonable turnaround time [89]. Facing these issues and tackling specifically extraction
procedures of nucleic acid which are crucial [90], the European Aspergillus PCR initiative (EAPCRI)
was founded with the aim of standardizing Aspergillus PCR methodology [91]. While this was a step in
the right direction, widespread acceptance and standardization is still lacking.
1.4. The Ugly
The good diagnostic performance and ability to detect azole resistance makes Aspergillus PCR from
blood specimens an attractive option for screening and diagnosis in neutropenic patients, while lack of
standardization and bad performance in non-neutropenic patients are the most important drawbacks.
There is one additional development that turns out to be the ugliest enemy of broad implementation
of Aspergillus PCR from blood specimens, namely the advent of mold-active antifungal prophylaxis.
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More than a decade ago, mold-active prophylaxis was shown to significantly decrease the prevalence of
IFI and increase overall survival in patients with acute leukemia with prolonged neutropenia undergoing
induction chemotherapy [29,32,92]. Reflecting this evidence, all major international guidelines now
strongly recommend mold-active prophylaxis for this setting [16,28,93], and the prophylaxis strategy has
now been adapted in most centers that treat patients with hematological malignancies. This development
turned out ugly for Aspergillus PCR from blood specimens because of its poor performance in patients
on systemic mold-active prophylaxes (Table 1). Only a few studies explicitly provide the exact number
of patients receiving antifungal treatment. Knowledge of the number of patients receiving antifungal
prophylaxis is important in order to reliably compare diagnostic performance of Aspergillus PCR
(see Table 1). A clear difference in settings applying antifungal treatment versus settings with no
antifungal treatment is noticeable and given the low sensitivity and specificity of Aspergillus PCR in this
population, its use is probably not supported in these circumstances.
In fact, Aspergillus PCR from blood specimens is unable to be used to diagnose breakthrough IA,
with sensitivities as low as 8% and 0% for probable and proven IA in single blood samples obtained
on the day of diagnostic bronchoscopy [62]. One may argue that due to the low fungal burden in
early breakthrough infections, the threshold of PCR assays needs to be lowered in order to make
detection possible. However, in another recent study in a setting where 100% of patients were receiving
mold-active prophylaxis/treatment lowering the cutoff produced a reasonable sensitivity, but this came
at the cost of unacceptable low specificities of 27.4% (95% CI 17.6%–39.1%) for one positive and 52.1%
(95% CI 40.0%–63.9%) for two positive Aspergillus PCR test results (15). The reasons for these strikingly
low specificities observed at those very low cut-offs are not fully understood, but several factors may
play a part. Importantly, while Candida spp. are predominant, Aspergillus spp. also represent a relevant
component of the gut mycobiome [94], detectable in 32% of studies and 24% of samples [95]. Low-level
translocation of fungal components from the gut may remain undetected in blood culture but may
trigger false positive PCR results after multiple amplification cycles [84,96]. In addition, antifungal
agents may increase the load of fungal DNA during the destruction of fungal cells, resulting in a large
load of fungal DNA and thus lowering specificity.
In contrast to blood PCR, Aspergillus PCR from BALF shows reasonable diagnostic performance
in patients receiving mold-active prophylaxis. According to recently published studies, the sensitivity
of PCR when applied to same-day BALF samples was significantly higher when compared to blood
samples reaching 44%–63% in patients on mold-active prophylaxis, with close to perfect specificity [62].
The use of PCR in prophylaxis settings may be restricted to the detection of breakthrough infections
and monitoring the response to therapy. Evidence for this usage is scant.
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Table 1. Performance of Aspergillus PCR in blood comparing settings with no antifungal prophylaxis versus settings with antifungal prophylaxis.
Author Patients Characteristics Patients(Samples)
IPA
Cases
Proportion of
Patients on
Antifungals
at Time of PCR
Material PCRAssay
Cut
off/Cycles
Sensitivity %
(95% CI)
Specificity %
(95% CI)
NPV
%/NLR PPV%/PLR DOR Reference
Cesaro et al. Hematologicalmalignancies
62 (536) 8 * 42%
Whole blood–single §§ Real time
PCR
45
88 37 95 17
- [97]Whole blood-multiple §§ 63 81 94 33
Eigl et al. Hematologicalmalignancies 53 (53) 16 * 64% Whole blood Nested - 0 (0–19.4)
100
(90.6–100.0) 70 NA NA
Boch et al. Hematologicalmalignancies 133 (138) 38 * 67% Whole blood Nested - 8 (3–20) 87 (70–95) 1.07
1 0.58 2 0.54 [62]
Hummel et al. Hematologicalmalignancies 91 (459) 30 * 70% Whole blood Nested
1–5
CFU/mL 43 - - - - [98]
Heldt et al. Hematologicalmalignancies 106 (106) 11 * 80% Serum Nested - 0 (0–27.8)
100
(93.5–100.0) 85 NA NA [99]
Aslan et al. Hematologicalmalignancies 99 (358) 18 * 90% Serum
Myc
Assay 45 65.0 (58.0–72.7) 57.8 (50.2–65.4) 51.7 50 - [100]
Springer et al. Hematological
malignancies 213 (2128) 9 * 100%
Serum–single §§ Real time
PCR
-
100.0
(39.8–100.0) 27.4 (17.6–39.1) 100 7.0 161 [15]
Serum–multiple §§ 50.0 (6.8–93.2) 52.1 (40.0–63.9) 95.0 5.4 1.1
Lass-Flörl et al. Hematologicalmalignancies or SOT 36 (205) *** 24 ** 100% Whole blood Traditional 34 44
§ 100 § 58 § - - [31]
Springer et al. Hematological
malignancies 46 3 * 100%
Whole blood–single §§ Real time
PCR
60
55 75 64 67
- [101]Whole blood–multiple §§ 27 100 60 100
Buchheidt et al.
Hematological
malignancies 218 (847) 33 **
0% 3
Serum Nested 5CFU/mL 91.7 81.3 98.0 49.3 - [102]
Da Silva et al. Hematologicalmalignancies 172 (1311) 20 * Whole blood Traditional 35 75.0 (50.6–90.4) 91.9 (86.5–95.3) 97.0 51.7 - [103]
Badiee et al. Hematologicalmalignancies 62 (230) 10 * Serum Nested
1
CFU/mL 80 96.2 88.9 92.6 - [104]
Springer et al. Hematological
malignancies 213 (2128) 17 *
Serum-single §§ Real time
PCR
60
92.9 (66.1–99.8) 73.1 (61.8–82.5) 98.3 38.2 34.5 [15]
Serum-multiple §§ 71.4 (41.9–91.6) 92.3 (84.0–97.1) 94.7 62.5 29.4
* proven/prob according to EORTC 2008. ** proven/prob according to EORTC 2002. *** only pts with proven/prob/poss IPA included. § for probable IPA. §§ single = one positive test
required; multiple = two or more positive tests required. # at time of PCR. 1 negative likelihood ratio. 2 positive likelihood ratio. 3 explicitly mentioned that NO antifungal prophylaxis
was administered.
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2. Conclusions
The diagnostic quality of Aspergillus PCR from blood is heavily dependent on a number of
influencing variables and therefore varies between settings. When used in the right patient cohort,
Aspergillus PCR from blood specimens may help diagnose or rule out IA. Due to its high NPV, PCR may
be used as a screening tool in neutropenic patients at high risk for IA and who are not receiving
mold-active prophylaxis. If there are no specific clinical signs of IA in conjunction with a single
negative PCR test result, empirical antifungal therapy can possibly be safely withheld, resulting in
a reduction of unnecessary use of antifungal agents and therefore a lower number of patients exposed to
potential drug toxicity. Regarding the role of PCR from blood specimens for confirming IA diagnosis in
neutropenic patients, recent studies have shown encouraging results when PCR is combined with other
antigen-based biomarkers such as GM. Consequently, positive PCR results show very high specificity
and can be used to trigger further diagnostic work-up or administration of empirical antifungal therapy
when infection is highly suspected. A combination of GM and PCR is preferable due to improved
diagnostic accuracy and the potential for more rapid diagnosis. Drawbacks of PCR testing include lack
of standardization, although things are improving since the EAPCRI started tackling this problem.
Thus, future research in terms of fungal PCRs is supposed to further address a standardization of PCR
assays to ensure comparability of study results and therefore enable the evaluation of PCR performance
in a significantly larger number of patients. This would also increase the number of patients with
proven IA, a usually underrepresented classification of IA in most studies, as most patients are classified
as having probable IA based on clinical and radiological signs of IA combined with a positive GM test.
In contrast, diagnostic utility of Aspergillus PCR from blood specimens is generally limited outside
the hematological malignancy setting, where BALF PCR is usually superior. The biggest hurdle
to broad implementation of Aspergillus PCR from blood specimens, however, is its poor diagnostic
performance in the presence of mold-active prophylaxis, which is now the standard of care in most
centers around the world in several patient settings. These developments largely limit the application
of Aspergillus PCR from blood specimens in those at highest risk. However, there are still areas
remaining where the test can be useful, particularly in neutropenic patients at moderate risk for IA for
whom antifungal prophylaxis is not (yet) recommended, including patients who develop prolonged
neutropenia during induction chemotherapy for acute lymphoid leukemia, or chemotherapy for other
hematologic malignancies.
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